Sara R. Fagerlie, PhD, CHCP
@cancercommunicator.com
Founder of CancerCommunicator.com - Dedicated to improving the care of patients with cancer through news and clinician education.
Pinned
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Want to see the lasted posts from #ASH25 or #SABCS25 check out the conference feed! #cansky #oncsky #medsky
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
December 6, 2025 at 6:15 PM
Reposted by Sara R. Fagerlie, PhD, CHCP
December 6, 2025 at 6:01 PM
Reposted by Sara R. Fagerlie, PhD, CHCP
#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML
www.cancercommunicator.com/oral-menin-b...
www.cancercommunicator.com/oral-menin-b...
December 6, 2025 at 6:03 PM
Reposted by Sara R. Fagerlie, PhD, CHCP
Symptom-based PFS CLL/SLL #ASH25
- 606 pts in ALPINE (zanu v ibru)
- longitudinal fatigue, insomnia, N/V associated with increased risk of PD (regardless of BTKi)
- zanu: lower odds of symptom worsening vs ibrutinib
More trial data demonstrating prognostic value of PROs! #leusm #lymsm
- 606 pts in ALPINE (zanu v ibru)
- longitudinal fatigue, insomnia, N/V associated with increased risk of PD (regardless of BTKi)
- zanu: lower odds of symptom worsening vs ibrutinib
More trial data demonstrating prognostic value of PROs! #leusm #lymsm
December 2, 2025 at 11:19 PM
Backdoor privatization of Medicare “When third-party entities are paid based on the volume of denied services, there is a clear risk that care that is medically necessary for certain patients will be inappropriately denied in pursuit of savings" www.kuow.org/stories/thou... #medsky #medicare
Thousands of Washington state Medicare users could soon have claims denied by AI
Starting Jan. 1, traditional Medicare recipients in Washington state will face a new hurdle to get certain procedures covered — private AI companies that get paid based on how many claims they deny.
www.kuow.org
December 2, 2025 at 2:29 PM
Backdoor privatization of Medicare “When third-party entities are paid based on the volume of denied services, there is a clear risk that care that is medically necessary for certain patients will be inappropriately denied in pursuit of savings" www.kuow.org/stories/thou... #medsky #medicare
"Nvidia and AMD and...Hewlett Packard Enterprise and Dell have already agreed to build facilities within the national labs...Some data will be shared with AI companies but...the government would withhold sensitive information that could put national security at risk" nyti.ms/3XR2uUG
Trump Orders Construction of A.I. Platform to Use Troves of Government Data for Research
www.nytimes.com
November 25, 2025 at 7:18 PM
"Nvidia and AMD and...Hewlett Packard Enterprise and Dell have already agreed to build facilities within the national labs...Some data will be shared with AI companies but...the government would withhold sensitive information that could put national security at risk" nyti.ms/3XR2uUG
Reposted by Sara R. Fagerlie, PhD, CHCP
Welcome to the Science feed!
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
February 10, 2024 at 3:08 PM
Welcome to the Science feed!
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/
Mod introductory posts linked below⬇️
Use the test tube emoji on posts you want to appear in the feed🧪
Please like the feed and make sure you follow our feed rules:
Reposted by Sara R. Fagerlie, PhD, CHCP
#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
October 18, 2025 at 3:30 PM
#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
#ESMODailyReporter➡️httpsef="https://ow.ly/YVy550XeuKH" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://ow.ly/YVy550XeuKH
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
October 17, 2025 at 7:08 PM
Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm
The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
dailyreporter.esmo.org
October 17, 2025 at 5:04 PM
The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm
Reposted by Sara R. Fagerlie, PhD, CHCP
At #ESMO25, explore how AI & digital tools are shaping oncology:
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
October 17, 2025 at 5:30 AM
At #ESMO25, explore how AI & digital tools are shaping oncology:
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
📌 AI-based image biomarkers
📌 Clinical trials in the age of AI
📌 Digital tools for off-site care
📌 ChatGPT & cancer care
📅 17–19 Oct
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
October 17, 2025 at 9:35 AM
It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇
Reposted by Sara R. Fagerlie, PhD, CHCP
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino - OncoDaily
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino / cancer, EMSO 2025, ESMO, ESMO25, Headlines, OncoDaily, Oncology, Paolo Tarantino
oncodaily.com
October 10, 2025 at 11:01 PM
Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
@ptarantinomd.bsky.social
oncodaily.com/voices/esmo2...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25
“We have a tendency to try to find a one-size-fits-all answer, and hormone therapy is one of the best examples of where one-size-fits-all answers do not work and lead to harmful decision making” @jama.com bit.ly/4mO0Qxr #medsky #womenshealth #menopause
Hormone Therapy for Menopause—A New Analysis of Old Data
This Medical News article discusses a new analysis of Women’s Health Initiative data that may help strengthen the understanding of menopausal hormone therapy’s benefits and risks for symptomatic women...
bit.ly
September 22, 2025 at 8:24 PM
“We have a tendency to try to find a one-size-fits-all answer, and hormone therapy is one of the best examples of where one-size-fits-all answers do not work and lead to harmful decision making” @jama.com bit.ly/4mO0Qxr #medsky #womenshealth #menopause
Reposted by Sara R. Fagerlie, PhD, CHCP
Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25
September 20, 2025 at 2:35 PM
Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25
What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
September 12, 2025 at 8:10 PM
What’s behind the rise in GI cancers among young adults?
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Dr Marshall explores this in our latest #OncologyUnscripted.
🎥 Watch here: clinicalcaresolutions.net/activities/o...
#GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC
Final OS from FLAURA2 at #WCLC25:
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
#WCLC25: Four-Year Median OS with Osimertinib/Chemotherapy Combination in Advanced EGFR-Mutation Positive NSCLC
The final overall survival (OS) analysis from the FLAURA2 trial was presented during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC) Pres...
www.cancercommunicator.com
September 8, 2025 at 9:59 PM
Final OS from FLAURA2 at #WCLC25:
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC.
👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02)
👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky
Reposted by Sara R. Fagerlie, PhD, CHCP
MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k
#WCLC25 | @iaslc.bsky.social
#WCLC25 | @iaslc.bsky.social
September 7, 2025 at 6:52 AM
MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k
#WCLC25 | @iaslc.bsky.social
#WCLC25 | @iaslc.bsky.social
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
September 6, 2025 at 5:58 PM
📢 Introducing Cancer Conference Hub
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more.
👉 Explore the hub here: bsky.app/profile/did:...
Catch the latest updates from #WCLC25 — clinical data, expert insights, and practice-changing news, all in one place.
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
September 6, 2025 at 5:50 PM
Catch the latest updates from #WCLC25 — clinical data, expert insights, and practice-changing news, all in one place.
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky
👉 Follow the curated feed here: Cancer Communicator | WCLC25
#LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky